Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
| Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nelfinavir | N/A | N/A | 8.4034 | 9.7440 | 15.4339 | -0.8211 | -0.6445 | -0.2989 | -1.0000 | -1.0000 | -0.8006 | 1.6805 | 2.3548 | 2.7767 | 0.1130 | 0.1589 | 0.1970 | 12.4011 | 15.3815 | 22.7642 | |
| Methotrexate | DHFR | Metabolism | 0.1850 | 100.0000 | 100.0000 | 0.3067 | 0.6372 | 0.9078 | 0.3672 | 0.5884 | 0.9117 | 0.0000 | 2.3582 | 4.5415 | 0.0328 | 0.2767 | 0.4502 | 0.0331 | 0.1737 | 100.0000 | |
| Geldanamycin | HSP90 | HSP90 | 0.0092 | 0.0240 | 0.0425 | -0.4324 | -0.2962 | -0.0904 | -0.3507 | -0.2347 | -0.0323 | 1.6732 | 2.3748 | 3.3908 | 0.6486 | 0.7709 | 0.9035 | 0.0116 | 0.0269 | 0.0560 | |
| Sunitinib | PDGFR/VEGFR/KIT/FLT3 | RTK | 4.8478 | 6.2817 | 9.9436 | -0.9902 | -0.9623 | -0.8818 | -0.9966 | -0.9683 | -0.8864 | 1.4527 | 2.4005 | 3.5359 | 0.3679 | 0.4354 | 0.4695 | 8.0047 | 9.6271 | 12.8243 | |
| MG-132 | Proteasome | Proteasome | 0.1071 | 0.1768 | 0.5078 | -0.8632 | -0.7505 | -0.5413 | -0.8499 | -0.6667 | -0.5123 | 1.5044 | 2.4128 | 3.5768 | 0.6530 | 0.7329 | 0.8677 | 0.1559 | 0.2469 | 1.0059 | |
| Purvalanol A | CDK1 | CDK | 25.2896 | 54.7310 | 100.0000 | 0.0757 | 0.5333 | 0.7416 | -0.0675 | 0.5068 | 0.7450 | 1.0817 | 2.5000 | 4.2404 | 0.0335 | 0.0774 | 0.1767 | 18.1854 | 35.4887 | 52.3768 | |
| NSC 663284 | CDC25 | CDC | 1.6689 | 2.2519 | 3.0742 | -0.9668 | -0.9336 | -0.8607 | -0.9846 | -0.9413 | -0.8554 | 1.8405 | 2.5456 | 4.2988 | 0.5484 | 0.5805 | 0.6318 | 2.2603 | 3.4718 | 5.7633 | |
| Baicalein | Lipoxygenase | Metabolism | 41.6425 | 70.6950 | 100.0000 | -0.0508 | 0.2583 | 0.5386 | -0.5772 | 0.0203 | 0.4255 | 1.6411 | 2.5826 | 3.9209 | 0.0595 | 0.1090 | 0.1450 | 32.6213 | 62.3319 | 100.0000 | |
| GSK1838705A | IGF1R | RTK | 4.0665 | 10.9435 | 23.1329 | -0.6969 | -0.3849 | -0.1067 | -0.7773 | -0.4275 | -0.2150 | 1.5275 | 2.6721 | 3.2208 | 0.2264 | 0.2964 | 0.4149 | 2.6121 | 7.6760 | 17.5013 | |
| Imatinib | ABL/KIT/PDGFR | nRTK | 18.5481 | 21.7914 | 25.5570 | -0.9852 | -0.9632 | -0.8948 | -0.9969 | -0.9814 | -0.8936 | 2.2328 | 2.7060 | 3.3541 | 0.3997 | 0.4467 | 0.4851 | 27.9144 | 31.9309 | 36.9254 | |
| Olomoucine II | CDK1 | CDK | 3.7444 | 6.0358 | 7.3956 | -0.7023 | -0.3927 | -0.1441 | -0.7230 | -0.4357 | -0.1137 | 1.4260 | 2.7083 | 4.7257 | 0.2563 | 0.3202 | 0.3981 | 5.9885 | 7.0813 | 8.6384 | |
| GSK461364 | PLK1 | PLK | 0.0087 | 0.0183 | 0.0805 | -0.6111 | -0.4222 | -0.2111 | -0.4745 | -0.3080 | -0.0919 | 2.4728 | 2.7172 | 4.9263 | 0.4701 | 0.6125 | 0.7345 | 0.0105 | 0.0265 | 0.3325 | |
| JNK-IN-5A | JNK | JNK | 1.8491 | 14.2132 | 100.0000 | -0.1818 | 0.1302 | 0.4971 | -0.4099 | 0.0435 | 0.4984 | 0.0000 | 3.1821 | 4.9999 | 0.0989 | 0.2367 | 0.3549 | 1.4898 | 12.5032 | 100.0000 | |
| XRP44X | ELK3 | MAPK | 0.7816 | 1.1482 | 1.8976 | -0.2021 | 0.0602 | 0.2789 | -0.1369 | 0.0575 | 0.2934 | 1.8769 | 3.3942 | 4.9998 | 0.2905 | 0.3686 | 0.4637 | 0.6561 | 1.0109 | 1.3678 | |
| IKK16 | IKK | NFKB | 1.8767 | 3.1049 | 3.8519 | -0.9668 | -0.9445 | -0.8619 | -0.9890 | -0.9578 | -0.8641 | 2.2018 | 3.4729 | 4.3592 | 0.3739 | 0.4332 | 0.4763 | 3.1521 | 4.0389 | 4.8853 |